How does Vaso's performance and valuation metrics compare to its primary competitors in the MedTech and healthcare IT space?

Performance vs. peers – Vaso’s Q2‑25 release showed a double‑digit top‑line increase (≈12% YoY) driven by its network‑IT services and the rollout of a new proprietary wound‑care device. The segment margins improved to ~14%, up from 10% a year ago, while the overall EBITDA margin moved to ~13%, still modest compared with large‑cap MedTech peers (Medtronic ~21%, Philips Healthcare ~19%). Vaso’s revenue base (~$85 million) is an order of magnitude smaller than those peers, so its growth rate looks attractive, but the absolute scale and cash conversion remain limited. The company posted positive free cash flow of ~$4 million, whereas many of its larger competitors are cash‑flow positive but operating at much higher absolute levels.

Valuation comparison – Trading on the OTCQX, Vaso is priced at roughly $1.30/sh, yielding an EV/EBITDA of ~8‑9× and a price‑to‑sales multiple of ~4.5×. By contrast, comparable publicly‑listed health‑IT names (e.g., Cerner/Oracle health‑cloud, Athenahealth) trade at EV/EBITDA of 12‑15× and P/S above 6×, while pure‑play MedTech giants command P/E ratios of 20‑25×. The discount reflects Vaso’s smaller size, higher execution risk, and lower liquidity, but it also offers a “value‑plus‑growth” angle for risk‑tolerant investors.

Trading take‑away – The market is rewarding Vaso’s earnings beat with a 3‑4% price rally and the stock is holding just above its $1.20 support and below the $1.45 resistance that aligns with the 50‑day moving average. A breakout above $1.45 on volume could signal a short‑term upside swing, making a small‑position “buy‑on‑breakout” viable for traders looking for a high‑growth, low‑multiple play. Conversely, a slip back below $1.20 may trigger a stop‑loss and suggest the market is re‑pricing the execution risk. Keep an eye on any forward‑guidance updates or partnership announcements, as those can quickly shift the risk‑reward balance relative to the higher‑multiple MedTech and health‑IT peers.